Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis and regulates cell migration and fibrosis. Preclinical studies using genetically altered mice and biological or small molecule inhibitors have elucidated a role for PAI-1 in the pathogenesis of thrombosis, vascular remodeling, renal injury, and initiation of diabetes. Inhibition of PAI-1 is a potential therapeutic strategy in these diseases.
Abderrahmani, R., Francois, A., Buard, V., Benderitter, M., Sabourin, J.C., Crandall, D.L. et al. (2009) Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injury . Int J Radiat Oncol Biol Phys74: 942-948.
2.
Alessi, M.C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M. et al. (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes49: 1374-1380.
3.
Banfi, C., Mussoni, L., Ris, P., Cattaneo, M.G., Vicentini, L., Battaini, F. et al. (1999) Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res85: 208-217.
4.
Biemond, B.J., Levi, M., Coronel, R., Janse, M.J., ten Cate, J.W. and Pannekoek, H. ( 1995) Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation91: 1175-1181.
5.
Bouchie, J.L., Hansen, H. and Feener, E.P. ( 1998) Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol18: 1771-1779.
6.
Brown, N.J., Agirbasli, M.A. and Vaughan, D.E. ( 1999) Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension34: 285-290.
7.
Brown, N.J., Kim, K.S., Chen, Y.Q., Blevins, L.S., Nadeau, J.H., Meranze, S.G. et al. (2000) Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab85: 336-344.
8.
Cale, J.M., Li, S.H., Warnock, M., Su, E.J., North, P.R., Sanders, K.L. et al. (2010) Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem285: 7892-7902.
9.
Carmeliet, P., Bouche, A., De, C.C., Janssen, S., Pollefeyt, S., Wyns, S. et al. (1995) Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann N Y Acad Sci748: 367-381.
10.
Carmeliet, P., Stassen, J.M., Schoonjans, L., Ream, B., van den Oord, J.J., De, M.M. et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice.II.Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest92: 2756-2760.
11.
Chen, Y.Q., Su, M., Walia, R.R., Hao, Q., Covington, J.W. and Vaughan, D.E. ( 1998) Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem273: 8225-8231.
12.
Chong, N.W., Codd, V., Chan, D. and Samani, N.J. ( 2006) Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett580: 4469-4472.
13.
Crandall, D.L., Quinet, E.M., El Ayachi, S., Hreha, A.L., Leik, C.E., Savio, D.A. et al. (2006) Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol26: 2209-2215.
14.
D’Agostino Jr, R.B., Hamman, R.F., Karter, A.J., Mykkanen, L., Wagenknecht, L.E. and Haffner, S.M. and Insulin Resistance Atherosclerosis Study Investigators. ( 2004) Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care27: 2234-2240.
15.
Dawson, S., Hamsten, A., Wiman, B., Henney, A. and Humphries, S. ( 1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator-1 activity. Arterioscler Thromb11: 183-190.
16.
Dawson, S.J., Wiman, B., Hamsten, A., Green, F., Humphries, S. and Henney, A.M. ( 1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem268: 10739-10745.
17.
De Taeye, B.M., Novitskaya, T., Gleaves, L., Covington, J.W. and Vaughan, D.E. ( 2006) Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem281: 32796-32805.
18.
de Waard, V., Arkenbout, E.K., Carmeliet, P., Lindner, V. and Pannekoek, H. ( 2002) Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol22: 1978-1983.
19.
Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S. and Gauthier, J.M. ( 1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene . EMBO Journal17: 3091-3100.
20.
Descheemaeker, K.A., Wyns, S., Nelles, L., Auwerx, J., Ny, T. and Collen, D. ( 1992) Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem267: 15086-15091.
21.
Eddy, A.A.(2009) Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost101: 656-664.
22.
Edgtton, K.L., Gow, R.M., Kelly, D.J., Carmeliet, P. and Kitching, A.R. ( 2004) Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int66: 68-76.
23.
Eitzman, D.T., Fay, W.P., Lawrence, D.A., Francis-Chmura, A.M., Shore, J.D., Olson, S.T. et al. (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest95: 2416-2420.
24.
Eitzman, D.T., McCoy, R.D., Zheng, X., Fay, W.P., Shen, T., Ginsburg, D. et al. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest97: 232-237.
25.
Eitzman, D.T., Westrick, R.J., Xu, Z., Tyson, J. and Ginsburg, D. ( 2000) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood96: 4212-4215.
26.
Elokdah, H., Abou-Gharbia, M., Hennan, J.K., McFarlane, G., Mugford, C.P., Krishnamurthy, G. et al. (2004) Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization . J Med Chem47: 3491-3494.
27.
Eriksson, P., Kallin, B., Hooft, F.M., Bavenholm, P. and Hamsten, S. ( 1995) Allele specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction . Proc Natl Acad Sci U S A92: 1851-1855.
28.
Eriksson, P., Nilsson, L., Karpe, F. and Hamsten, A. ( 1998) Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol18: 20-26.
29.
Fay, W.P., Parker, A.C., Condrey, L.R. and Shapiro, A.D. ( 1997) Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene . Blood90: 204-208.
30.
Feener, E.P., Northrup, J.M., Aiello, L.P. and King, G.L. ( 1995) Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest95: 1353-1362.
31.
Fejes-Toth, G. and Naray-Fejes-Toth, A. ( 2007) Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology148: 1502-1510.
32.
Folsom, A.R., Qamhieh, H.T., Wing, R.R., Jeffery, R.W., Stinson, V.L., Kuller, L.H. et al. (1993) Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb13: 162-169.
33.
Friederich, P.W., Levi, M., Biemond, B.J., Charlton, P., Templeton, D., van Zonneveld, A.J. et al. (1997) Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation96: 916-921.
34.
Gardell, S.J., Krueger, J.A., Antrilli, T.A., Elokdah, H., Mayer, S., Orcutt, S.J. et al. (2007) Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action . Mol Pharmacol72: 897-906.
35.
Gerstein, H.C., Yusuf, S., Bosch, J., Pogue, J., Sheridan, P., Dinccag, N. et al. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone). (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368: 1096-1105.
36.
Gils, A. and Declerck, P.J. ( 2004) Plasminogen activator inhibitor-1. Curr Med Chem11: 2323-2334.
37.
Gonzalez, J., Klein, J., Chauhan, S.D., Neau, E., Calise, D., Nevoit, C. et al. (2009) Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis. Exp Biol Med (Maywood) 234: 1511-1518.
38.
Gorlatova, N.V., Cale, J.M., Elokdah, H., Li, D., Fan, K., Warnock, M. et al. (2007) Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem282: 9288-9296.
39.
Grant, P.J. ( 2007) Diabetes mellitus as a prothrombotic condition. J Intern Med262: 157-172.
40.
Hamaguchi, E., Takamura, T., Shimizu, A. and Nagai, Y. ( 2003) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther307: 987-994.
41.
Hamsten, A., de Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C. et al. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. LancetII: 3-9.
42.
Hamsten, A., Wiman, B., deFaire, U. and Blomback, M. ( 1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med313: 1557-1563.
Healy, A.M. and Gelehrter, T.D. ( 1994) Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem269: 19095-19100.
45.
Hennan, J.K., Morgan, G.A., Swillo, R.E., Antrilli, T.M., Mugford, C., Vlasuk, G.P. et al. (2008) Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost6: 1558-1564.
46.
Hertig, A., Berrou, J., Allory, Y., Breton, L., Commo, F., Costa De Beauregard, M.A. et al. (2003) Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J17: 1904-1906.
47.
Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J. and Ferrara, N. ( 1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem267: 26031-26037.
48.
Huang, Y., Border, W.A., Lawrence, D.A. and Noble, N.A. ( 2006a) Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int70: 515-522.
49.
Huang, Y., Border, W.A., Lawrence, D.A. and Noble, N.A.(2009) Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol297: F1045-F1054.
50.
Huang, Y., Haraguchi, M., Lawrence, D.A., Border, W.A., Yu, L. and Noble, N.A. ( 2003) A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest112: 379-388.
51.
Huang, Y., Wongamorntham, S., Kasting, J., McQuillan, D., Owens, R.T., Yu, L. et al. (2006b) Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int69: 105-113.
52.
Ingelsson, E., Pencina, M.J., Tofler, G.H., Benjamin, E.J., Lanier, K.J., Jacques, P.F. et al. (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation116: 984-992.
53.
Izuhara, Y., Takahashi, S., Nangaku, M., Takizawa, S., Ishida, H., Kurokawa, K. et al. (2008) Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol28: 672-677.
54.
Izuhara, Y., Yamaoka, N., Kodama, H., Dan, T., Takizawa, S., Hirayama, N. et al. (2010) A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab30: 904-912.
55.
Jain, M.R., Shetty, S., Chakrabarti, G., Pandya, V., Sharma, A., Parmar, B. et al. (2008) In vitro PAI-1 inhibitory activity of oxalamide derivatives. Eur J Med Chem43: 880-884.
56.
Kaikita, K., Fogo, A.B., Ma, L.-J., Schoenhard, J.A., Brown, N.J. and Vaughan, D.E. ( 2001) Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to chronic nitric oxide synthase inhibition. Circulation104: 839-844.
57.
Kerins, D.M., Hao, Q. and Vaughan, D.E. ( 1995) Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest96: 2515-2520.
58.
Kitching, A.R., Kong, Y.Z., Huang, X.R., Davenport, P., Edgtton, K.L., Carmeliet, P. et al. (2003) Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis . J Am Soc Nephrol14: 1487-1495.
59.
Lawrence, D.A., Olson, S.T., Muhammad, S., Day, D.E., Kvassman, J.O., Ginsburg, D. et al. (2000) Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A. J Biol Chem275: 5839-5844.
60.
Lawrence, D.A., Palaniappan, S., Stefansson, S., Olson, S.T., Francis-Chmura, A.M., Shore, J.D. et al. (1997) Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin.Implications for the regulation of pericellular proteolysis. J Biol Chem272: 7676-7680.
61.
Lijnen, H.R. ( 2001) Plasmin and matrix metalloproteinases in vascular remodeling . Thromb Haemost86: 324-333.
62.
Lijnen, H.R. ( 2005a) Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thromb Haemost93: 816-819.
Lijnen, H.R., Maquoi, E., Morange, P., Voros, G., van Hoef, B., Kopp, F. et al. (2003) Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol23: 78-84.
65.
Loskutoff, D.J. and Quigley, J.P. ( 2000) PAI-1, fibrosis, and the elusive provisional fibrin matrix . J Clin Invest106: 1441-1443.
66.
Luther, J.M., Wang, Z., Ma, J., Makhanova, N., Kim, H.S. and Brown, N.J.(2009) Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology150: 2229-2236.
67.
Lyons, R.M., Gentry, L.E., Purchio, A.F. and Moses, H.L. ( 1990) Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol110: 1361-1367.
68.
Ma, J., Albornoz, F., Yu, C., Byrne, D.W., Vaughan, D.E. and Brown, N.J. ( 2005) Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. Hypertension46: 313-320.
69.
Ma, J., Weisberg, A., Griffin, J.P., Vaughan, D.E., Fogo, A.B. and Brown, N.J. ( 2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int69: 1064-1072.
70.
Ma, L.J., Mao, S.L., Taylor, K.L., Kanjanabuch, T., Guan, Y., Zhang, Y. et al. (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes53: 336-346.
71.
Ma, L.J., Yang, H., Gaspert, A., Carlesso, G., Barty, M.M., Davidson, J.M. et al. (2003) Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol163: 1261-1273.
72.
Matsuo, S., Lopez-Guisa, J.M., Cai, X., Okamura, D.M., Alpers, C.E., Bumgarner, R.E. et al. (2005) Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int67: 2221-2238.
73.
Morange, P.E., Lijnen, H.R., Alessi, M.C., Kopp, F., Collen, D. and Juhan-Vague, I. ( 2000) Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol20: 1150-1154.
74.
Moriwaki, H., Stempien-Otero, A., Kremen, M., Cozen, A.E. and Dichek, D.A. ( 2004) Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice . Circ Res95: 637-644.
75.
Murphy, G., Stanton, H., Cowell, S., Butler, G., Knauper, V., Atkinson, S. et al. (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS107: 38-44.
76.
Nicholas, S.B., Aguiniga, E., Ren, Y., Kim, J., Wong, J., Govindarajan, N. et al. (2005) Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int67: 1297-1307.
77.
Numaguchi, Y., Ishii, M., Kubota, R., Morita, Y., Yamamoto, K., Matsushita, T. et al. (2009) Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. Arterioscler Thromb Vasc Biol29: 2102-2108.
78.
Nykjaer, A., Conese, M., Christensen, E.I., Olson, D., Cremona, O., Gliemann, J. et al. (1997) Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J16: 2610-2620.
79.
Oda, T., Jung, Y.O., Kim, H.S., Cai, X., Lopez-Guisa, J.M., Ikeda, Y. et al. (2001) PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int60: 587-596.
80.
Oestreicher, E.M., Martinez-Vasquez, D., Stone, J.R., Jonasson, L., Roubsanthisuk, W., Mukasa, K. et al. (2003) Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/ NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation108: 2517-2523.
81.
Pahor, M., Franse, L.V., Deitcher, S.R., Cushman, W.C., Johnson, K.C., Shorr, R.I. et al. (2002) Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1 . Circulation105: 457-461.
82.
Peng, L., Bhatia, N., Parker, A.C., Zhu, Y. and Fay, W.P. ( 2002) Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol22: 934-939.
83.
Ploplis, V.A., Cornelissen, I., Sandoval-Cooper, M.J., Weeks, L., Noria, F.A. and Castellino, F.J. ( 2001) Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol158: 107-117.
84.
Rupin, A., Gaertner, R., Mennecier, P., Richard, I., Benoist, A., De, N.G. et al. (2008) S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thromb Res122: 265-270.
85.
Saksela, O. and Rifkin, D.B. ( 1990) Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol110: 767-775.
86.
Samarakoon, R. and Higgins, P.J. ( 2008) Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost100: 976-983.
87.
Schafer, K., Schroeter, M.R., Dellas, C., Puls, M., Nitsche, M., Weiss, E. et al. (2006) Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol26: 1254-1259.
88.
Scheen, A.J. ( 2004) Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs64: 2537-2565.
89.
Schneider, D.J., Hayes, M., Wadsworth, M., Taatjes, H., Rincon, M., Taatjes, D.J. et al. (2004) Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1) . J Histochem.Cytochem52: 1091-1099.
90.
Schneider, D.J., Ricci, M.A., Taatjes, D.J., Baumann, P.Q., Reese, J.C., Leavitt, B.J. et al. (1997) Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol17: 3294-3301.
91.
Schneider, D.J. and Sobel, B.E. ( 1991) Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A88: 9959-9963.
92.
Smith, L.H., Dixon, J.D., Stringham, J.R., Eren, M., Elokdah, H., Crandall, D.L. et al. (2006) Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood107: 132-134.
93.
Stefansson, S. and Lawrence, D.A. ( 1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature383: 441-443.
94.
Stefansson, S. and Lawrence, D.A. ( 2003) Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE2003: e24.
95.
Stempien-Otero, A., Plawman, A., Meznarich, J., Dyamenahalli, T., Otsuka, G. and Dichek, D.A. ( 2006) Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem281: 15345-15351.
96.
Thogersen, A.M., Jansson, J.H. and Wester, P.O. ( 1996) Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction. Int J Cardiol56: 53-59.
97.
van Giezen, J.J., Wahlund, G., Nerme. and Abrahamsson, T. ( 1997) The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis . Thromb Haemost77: 964-969.
98.
van Hinsbergh, V., Kooistra, T., van den Berg, E.A., Princen, H.M., Fiers, W. and Emeis, J.J. ( 1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo . Blood72: 1467-1473.
99.
Vaughan, D.E., Lazos, S.A. and Tong, K. ( 1995) Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest95: 995-1001.
Wiklund, P.G., Nilsson, L., Ardnor, S.N., Eriksson, P., Johansson, L., Stegmayr, B. et al. (2005) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke36: 1661-1665.
102.
Witkowski, P., Seki, T., Xiang, G., Martens, T., Sondermeijer, H., See, F. et al. (2007) A DNA enzyme against plasminogen activator inhibitor- type 1 (PAI-1) limits neointima formation after angioplasty in an obese diabetic rodent model. J Cardiovasc Pharmacol50: 633-640.
Ye, Z., Liu, E.H., Higgins, J.P., Keavney, B.D., Lowe, G.D., Collins, R. et al. (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet367: 651-658.
105.
Zhu, Y., Carmeliet, P. and Fay, W.P. ( 1999) Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation99: 3050-3055.
106.
Zhu, Y., Farrehi, P.M. and Fay, W.P. ( 2001) Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation103: 3105-3110.
